- Home
- INSM vs SOFI Comparison
INSM vs SOFI Comparison
Compare INSM & SOFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSM
- SOFI
- Stock Information
- Founded
- INSM 1988
- SOFI 2011
- Country
- INSM United States
- SOFI United States
- Employees
- INSM N/A
- SOFI N/A
- Industry
- INSM Biotechnology: Pharmaceutical Preparations
- SOFI Diversified Financial Services
- Sector
- INSM Health Care
- SOFI Finance
- Exchange
- INSM Nasdaq
- SOFI Nasdaq
- Market Cap
- INSM 14.3B
- SOFI 16.6B
- IPO Year
- INSM 2000
- SOFI N/A
- Fundamental
- Price
- INSM $81.06
- SOFI $14.67
- Analyst Decision
- INSM Strong Buy
- SOFI Hold
- Analyst Count
- INSM 15
- SOFI 16
- Target Price
- INSM $92.00
- SOFI $12.18
- AVG Volume (30 Days)
- INSM 1.8M
- SOFI 45.4M
- Earning Date
- INSM 02-20-2025
- SOFI 01-27-2025
- Dividend Yield
- INSM N/A
- SOFI N/A
- EPS Growth
- INSM N/A
- SOFI N/A
- EPS
- INSM N/A
- SOFI 0.39
- Revenue
- INSM $363,707,000.00
- SOFI $2,643,147,000.00
- Revenue This Year
- INSM $20.03
- SOFI N/A
- Revenue Next Year
- INSM $41.61
- SOFI $20.04
- P/E Ratio
- INSM N/A
- SOFI $37.16
- Revenue Growth
- INSM 19.17
- SOFI 27.82
- 52 Week Low
- INSM $21.92
- SOFI $6.01
- 52 Week High
- INSM $84.87
- SOFI $18.42
- Technical
- Relative Strength Index (RSI)
- INSM 58.18
- SOFI 42.97
- Support Level
- INSM $79.50
- SOFI $14.42
- Resistance Level
- INSM $80.28
- SOFI $17.11
- Average True Range (ATR)
- INSM 2.98
- SOFI 0.67
- MACD
- INSM 0.06
- SOFI -0.04
- Stochastic Oscillator
- INSM 63.38
- SOFI 9.29
About INSM Insmed Incorporated
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
About SOFI SoFi Technologies Inc.
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.